Data Encourages Clinicians to Move and Assess These Biomarkers in All Ongoing Trials

Data Encourages Clinicians to Move and Assess These Biomarkers in All Ongoing Trials

User Photo
aacr2017

3 years
1,528 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Solange Peters, MD, PhD of Lausanne University Hospital discusses the impact of Checkmate-026 on current cancer research, stating the data encourages clinicians to move and assess the biomarkers in all ongoing trials. She also argues that the biomarker can help predict which patients will benefit from early therapeutic treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Up Next Autoplay
User Photo